Novartis pulls ahead of Merck in MET-positive lung cancer race - PMLiVE
Capmatinib (INC280) | Selective MET Inhibitor | MedChemExpress
Merck's targeted lung cancer drug tepotinib wins early access in UK -
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
Novartis bags FDA priority review in tight lung cancer race against Merck KGaA | Fierce Pharma
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
Met Kinase Inhibitor | CAS 658084-23-2 | SCBT - Santa Cruz Biotechnology
Biomedicines | Free Full-Text | Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment | HTML
MET-dependent solid tumours — molecular diagnosis and targeted therapy | Nature Reviews Clinical Oncology
Novartis' MET inhibitor Tabrecta wins permit for lung cancer in Korea < Pharma < 기사본문 - KBR
Novartis promising anti-tumor combination therapy - K-Recruiting
Novartis beats Merck KGaA to U.S. finish line with targeted lung cancer drug Tabrecta | Fierce Pharma
Novartis announces MET inhibitor Tabrecta™ approved in Japan for advanced non-small cell lung cancer with METex14 | Novartis
Safety of Tepotinib in Patients with MET Exon 14 Skipping NSCLC and Recommendations for Management - Clinical Lung Cancer
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews
Novartis' Powerful MET Inhibitor Tabrecta Has A Strong Therapeutic Effect On METex14 Mutant Non-small Cell Lung Cancer (NSCLC)! - Industry news - News - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd
Novartis investigational lung cancer therapy capmatinib (INC280) granted FDA Breakthrough Therapy Designation for patients with MET-mutated advanced non-small cell lung cancer | Novartis
FDA approval for Tabrecta in metastatic non-small cell lung cancer with METex14 | Pharmafile
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study - The Lancet Oncology
A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor - Journal of Thoracic Oncology
Tabrecta (capmatinib) for the Treatment of Non-Small Cell Lung Cancer
Contemporary Developments in MET-Selective Kinase Inhibitors in Advanced Non–Small-Cell Lung Cancer
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
Schematic representation of MET signaling blockade by capmatinib.... | Download Scientific Diagram
JCM | Free Full-Text | The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer | HTML
